» Articles » PMID: 29283291

Structural Insights into Humanization of Anti-tissue Factor Antibody 10H10

Abstract

Murine antibody 10H10 raised against human tissue factor is unique in that it blocks the signaling pathway, and thus inhibits angiogenesis and tumor growth without interfering with coagulation. As a potential therapeutic, the antibody was humanized in a two-step procedure. Antigen-binding loops were grafted onto selected human frameworks and the resulting chimeric antibody was subjected to affinity maturation by using phage display libraries. The results of humanization were analyzed from the structural perspective through comparison of the structure of a humanized variant with the parental mouse antibody. This analysis revealed several hot spots in the framework region that appear to affect antigen binding, and therefore should be considered in human germline selection. In addition, some positions in the Vernier zone, e.g., residue 71 in the heavy chain, that are traditionally thought to be crucial appear to tolerate amino acid substitutions without any effect on binding. Several humanized variants were produced using both short and long forms of complementarity-determining region (CDR) H2 following the difference in the Kabat and Martin definitions. Comparison of such pairs indicated consistently higher thermostability of the variants with short CDR H2. Analysis of the binding data in relation to the structures singled out the ImMunoGeneTics information system® germline IGHV1-2*01 as dubious owing to two potentially destabilizing mutations as compared to the other alleles of the same germline and to other human germlines.

Citing Articles

Membrane-bound model of the ternary complex between factor VIIa/tissue factor and factor X.

Muller M, Mortenson A, Sedzro J, Wen P, Morrissey J, Tajkhorshid E Blood Adv. 2024; 9(4):729-740.

PMID: 39671302 PMC: 11869871. DOI: 10.1182/bloodadvances.2024014845.


Humanization of Pan-HLA-DR mAb 44H10 Hinges on Critical Residues in the Antibody Framework.

Kassardjian A, Ivanochko D, Barber B, Jetha A, Julien J Antibodies (Basel). 2024; 13(3).

PMID: 39051333 PMC: 11270187. DOI: 10.3390/antib13030057.


The influence of antibody humanization on shark variable domain (VNAR) binding site ensembles.

Fernandez-Quintero M, Fischer A, Kokot J, Waibl F, Seidler C, Liedl K Front Immunol. 2022; 13:953917.

PMID: 36177031 PMC: 9514858. DOI: 10.3389/fimmu.2022.953917.


Functional Characteristics and Regulated Expression of Alternatively Spliced Tissue Factor: An Update.

Matiash K, Lewis C, Bogdanov V Cancers (Basel). 2021; 13(18).

PMID: 34572880 PMC: 8471299. DOI: 10.3390/cancers13184652.


Germline-Dependent Antibody Paratope States and Pairing Specific V-V Interface Dynamics.

Fernandez-Quintero M, Kroell K, Bacher L, Loeffler J, Quoika P, Georges G Front Immunol. 2021; 12:675655.

PMID: 34447370 PMC: 8382685. DOI: 10.3389/fimmu.2021.675655.


References
1.
Ahamed J, Versteeg H, Kerver M, Chen V, Mueller B, Hogg P . Disulfide isomerization switches tissue factor from coagulation to cell signaling. Proc Natl Acad Sci U S A. 2006; 103(38):13932-7. PMC: 1599891. DOI: 10.1073/pnas.0606411103. View

2.
Wark K, Hudson P . Latest technologies for the enhancement of antibody affinity. Adv Drug Deliv Rev. 2006; 58(5-6):657-70. DOI: 10.1016/j.addr.2006.01.025. View

3.
King D, Bowers P, Kehry M, Horlick R . Mammalian cell display and somatic hypermutation in vitro for human antibody discovery. Curr Drug Discov Technol. 2013; 11(1):56-64. DOI: 10.2174/15701638113109990037. View

4.
McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, Read R . Phaser crystallographic software. J Appl Crystallogr. 2009; 40(Pt 4):658-674. PMC: 2483472. DOI: 10.1107/S0021889807021206. View

5.
North B, Lehmann A, Dunbrack Jr R . A new clustering of antibody CDR loop conformations. J Mol Biol. 2010; 406(2):228-56. PMC: 3065967. DOI: 10.1016/j.jmb.2010.10.030. View